Compared with placebo, semaglutide achieved larger reductions in heavy-drinking days (−41.1 vs −26.4 percentage points) and ...
Axena Health, Inc., a women's health company redefining the standard of care for pelvic health conditions through clinically proven, non-invasive treatments, today announced a new publication entitled ...
Breast cancer survivors who maintain an exercise routine suited to their personal needs may improve their long-term survival, a new study suggests. The study, designed as a so-called target trial ...
Results from a small randomized controlled clinical trial show promising findings about a new type of therapy for patients ...
Johnson & Johnson has initiated the PERSIGMA randomized controlled trial (RCT), one of the first randomized studies ...
Bambusa Therapeutics, Inc. (Bambusa Therapeutics), a clinical-stage biotechnology company advancing next-generation bispecific antibodies for immunology and inflammation, today announced the ...
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial Patients with advanced lung cancer reporting at least moderate ...
Cost-Effectiveness of Total Neoadjuvant Therapy With Selective Nonoperative Management for Locally Advanced Rectal Cancer: Analysis of Data From the Organ Preservation for Rectal Adenocarcinoma Trial ...
Idiopathic normal-pressure hydrocephalus is a neurologic disorder characterized by impaired gait, balance, cognition, and bladder control in older adults. The disorder is treated with shunt surgery, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results